Merus’ (MRUS) Buy Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Merus (NASDAQ:MRUS) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $109.00 price objective on the biotechnology company’s stock.

MRUS has been the topic of several other research reports. Piper Sandler started coverage on Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Merus in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of Merus in a research report on Friday, February 7th. They set an “overweight” rating and a $91.00 target price on the stock. Finally, Citigroup upped their price target on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $85.31.

Merus Stock Performance

Shares of NASDAQ MRUS opened at $44.61 on Friday. The stock’s 50-day simple moving average is $43.98 and its 200-day simple moving average is $46.09. The firm has a market capitalization of $3.08 billion, a PE ratio of -11.29 and a beta of 1.15. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. On average, sell-side analysts forecast that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Merus

Institutional investors have recently added to or reduced their stakes in the business. State of Wyoming acquired a new stake in shares of Merus in the 4th quarter valued at approximately $48,000. Wells Fargo & Company MN raised its position in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Merus in the fourth quarter valued at $60,000. Avior Wealth Management LLC purchased a new stake in shares of Merus during the 4th quarter worth $76,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Merus during the 4th quarter worth $84,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.